In conclusion, this work demonstrates the potential of vaccination against AR and AR-V7 as immunotherapies in prostate cancer and implies that vaccination against AR-V7 or other AR-Vs associated with treatment resistance could treat or inhibit the development of these resistance mechanisms, particularly in combination with immune checkpoint inhibitors. This evidence concerns the gene AR and prostate cancer.